Overview

Anticoagulant Using Rivaroxaban on Top of Aspirin Versus Antiplatelet Therapy in Intracranial Atherostenosis Stenosis

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis. Participants will be divided into 2 groups to receive either oral rivaroxaban plus aspirin or oral clopidogrel plus aspirin. The main question it aims to answer is whether the experimental group (oral rivaroxaban plus aspirin) is superior to the control group ( oral clopidogrel plus aspirin) to lower recurrent stroke/TIA or death in these patients during 1 year of follow-up.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Collaborator:

National Natural Science foundaton of China

Treatments:

Aspirin
Clopidogrel
Rivaroxaban